[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342146-105":59,"doc-detail-342146-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","albumin-to-alkaline-phosphatase-ratio-as-a-new-early-predictive-marker-of-axillary-response-in-breast-cancer-patients-undergoing-neoadjuvant-chemotherapy-a-pilot-study","Albumin-To-Alkaline Phosphatase Ratio as a New Early Predictive Marker of Axillary Response in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy: A Pilot Study","","The Albumin-to-Alkaline Phosphatase ratio (AAPR) is evaluated as an easily applicable, cost-effective biomarker for predicting treatment outcomes in breast cancer. Existing evidence links low AAPR to poor primary-tumor response to neoadjuvant chemotherapy, but axillary response data remain limited. This pilot study tests whether AAPR predicts axillary response in initially node-positive (cN+) patients receiving NAC. Clinical and biochemical variables are collected, AAPR is computed from pre-NAC albumin and alkaline phosphatase, and Fisher’s exact test compares high versus low AAPR groups using a literature cut-off. Nodal pCR occurs in 20/45 (44.4%) patients, and axillary pCR differs significantly between groups (p=0.03, OR=0.129).",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/albumin-to-alkaline-phosphatase-ratio-as-a-new-early-predictive-marker-of-axillary-response-in-breast-cancer-patients-undergoing-neoadjuvant-chemotherapy-a-pilot-study/342146/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/albumin-to-alkaline-phosphatase-ratio-as-a-new-early-predictive-marker-of-axillary-response-in-breast-cancer-patients-undergoing-neoadjuvant-chemotherapy-a-pilot-study/342146.png","ImageObject",300,407,{"name":92,"@type":93},"Evangeline","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-12","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the Albumin-to-Alkaline Phosphatase ratio (AAPR) used for in this study?","Question",{"text":112,"@type":113},"AAPR is assessed as an outcome predictor for breast cancer patients undergoing neoadjuvant chemotherapy, specifically to evaluate axillary response.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How is AAPR calculated and what cutoff is used?",{"text":117,"@type":113},"AAPR is calculated from pre-treatment serum albumin and alkaline phosphatase values, and groups are defined using a literature-reported cutoff.",{"name":119,"@type":110,"acceptedAnswer":120},"What does the study conclude about predicting axillary response?",{"text":121,"@type":113},"The pilot study suggests pre-treatment AAPR may serve as an early predictor of axillary response in initially node-positive (cN+) breast cancer patients receiving NAC.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},342146,1790680083,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},13056703019662,"https://ap-avatar.wpscdn.com/avatar/be000253a8e92610077?_k=1778726343310543188","medicina  \nArticle  \nAlbumin-To-Alkaline Phosphatase Ratio as a New Early Predictive Marker of Axillary Response in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy: A Pilot Study  \nRahel Felicia Mirjam Schmidt 1, Yves Harder 2,3, Lorenzo Rossi 4,5, Paola Canino 4,6, Simone Schiaffino 1,4,7, Arianna Calcinotto 1,8, Ulrike Perriard 4,9, Rossella Graffeo 4,5, Roberta Decio 4,10, Claudia Canonica 4,10, Marco Cuzzocrea 4,11, Ammad Ahmad Farooqi 12, Giorgia Elisabeth Colombo 10, Mirjam Diller 10,  \nNickolas Peradze 4,10, Andrea Papadia 1,10, Alberto Pagnamenta 1,13 and Maria Luisa Gasparri 1,4,10, *  \nCitation: Schmidt, R.F.M.; Harder, Y.; Rossi, L.; Canino, P.; Schiaffino, S.; Calcinotto, A.; Perriard, U.; Graffeo, R.; Decio, R.; Canonica, C.; et al. Albumin-To-Alkaline Phosphatase Ratio as a New Early Predictive Marker of Axillary Response in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy: A Pilot Study. Medicina 2024, 60, 1767 . [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)medicina60111767  \nAcademic Editor: Konstantinos Dimas  \nReceived: 7 October 2024  \nAccepted: 17 October 2024  \nPublished: 28 October 2024  \nCopyright: © 2024 by the authors. Published by MDPI on behalf of the Lithuanian University of Health Sciences. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)) .  \n1 Faculty of Biomedical Science, Università della Svizzera Italiana (USI), 6900 Lugano, Switzerland; rahel.schmidt@usi.ch (R.F.M.S.); simone.schiaffino@eoc.ch (S.S.); arianna.calcinotto@ior.usi.ch (A.C.); [andrea.papadia@eoc.ch](andrea.papadia@eoc.ch) (A.P.); [alberto.pagnamenta@eoc.ch](alberto.pagnamenta@eoc.ch) (A.P.)  \n2 Department of Plastic, Reconstructive and Aesthetic Surgery and Hand Surgery, Centre Hospitalier Universitaire Vaudois (CHUV), 1005 Lausanne, Switzerland; yves.harder@chuv.ch  \n3 Faculty of Biology and Medicine, University of Lausanne (UNIL), 1011 Lausanne, Switzerland  \n4 Centro di Senologia della Svizzera Italiana (CSSI), Ente Ospedaliero Cantonale (EOC), 6900 Lugano, Switzerland; [lorenzo.rossi@eoc.ch](lorenzo.rossi@eoc.ch) (L.R.); [paola.canino@eoc.ch](paola.canino@eoc.ch) (P.C.); [ulrike.perriard@eoc.ch](ulrike.perriard@eoc.ch) (U.P.); [rossella.graffeogalbiati@eoc.ch](rossella.graffeogalbiati@eoc.ch) (R.G.); [roberta.decio@eoc.ch](roberta.decio@eoc.ch) (R.D.); [claudia.canonica@eoc.ch](claudia.canonica@eoc.ch) (C.C.); [marco.cuzzocrea@eoc.ch](marco.cuzzocrea@eoc.ch) (M.C.); [nickolas.peradze@eoc.ch](nickolas.peradze@eoc.ch) (N.P.)  \n5 Istituto Oncologico della Svizzera Italiana (IOSI), Centro di Senologia della Svizzera Italiana, 6962 Lugano, Switzerland  \n6 Servizio di Radio-Oncologia, Istituto Oncologico della Svizzera Italiana, Ente Ospedaliere Cantonale (EOC), Centro di Senologia della Svizzera Italiana, 6962 Lugano, Switzerland  \n7 Servizio di Radiologia, Istituto Imaging della Svizzera Italiana, Ente Ospedaliere Cantonale (EOC), Centro di Senologia della Svizzera Italiana, 6962 Lugano, Switzerland  \n8 Cancer Immunotherapy Lab, Institute of Oncology Research (IOR), 6500 Bellinzona, Switzerland  \n9 Servizio di Istopatologia, Istituto Cantonale di Patologia, Ente Ospedaliere Cantonale (EOC), 6600 Locarno, Switzerland  \n10 Dipartimento di Ginecologia e Ostetricia, Ente Ospedaliere Cantonale (EOC), Centro di Senologia della Svizzera Italiana, 6962 Lugano, Switzerland; [giorgiaelisabeth.colombo@eoc.ch](giorgiaelisabeth.colombo@eoc.ch) (G.E.C.); [mirjam.diller@eoc.ch](mirjam.diller@eoc.ch) (M.D.)  \n11 Clinica di Medicina Nucleare, Ente Ospedaliere Cantonale (EOC), dell’Istituto Imaging della Svizzera Italiana, Ospedale Regionale di Bellinzona sede San Giovanni e Ospedale Regionale di Lugano sede Civico, 6900 Lugano, Switzerland  \n12","cbCailNqGXDXwjzZ","https://ap.wps.com/l/cbCailNqGXDXwjzZ","pdf",299631,"English","# Abstract\n## Background and Objectives\n## Materials and Methods\n## Results\n## Conclusions","[{\"question\":\"What is the Albumin-to-Alkaline Phosphatase ratio (AAPR) used for in this study?\",\"answer\":\"AAPR is assessed as an outcome predictor for breast cancer patients undergoing neoadjuvant chemotherapy, specifically to evaluate axillary response.\"},{\"question\":\"How is AAPR calculated and what cutoff is used?\",\"answer\":\"AAPR is calculated from pre-treatment serum albumin and alkaline phosphatase values, and groups are defined using a literature-reported cutoff.\"},{\"question\":\"What does the study conclude about predicting axillary response?\",\"answer\":\"The pilot study suggests pre-treatment AAPR may serve as an early predictor of axillary response in initially node-positive (cN+) breast cancer patients receiving NAC.\"}]","Albumin-To-Alkaline Phosphatase Ratio as a New Early Predictive Marker of Axillary Response in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy: A Pilot Study | PDF",1790045494,25,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d806ad3bb5e9eb9b321493bde99231f9.webp",983,1390,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6470913c4136d17c7ce47e7fa5d36765.webp",982,1388,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fbb0ff51f03e51b213c5a6afa8949836.webp",981,1387,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a1301a11dad260a4861999bacd806f88.webp",980,1385]